Changes in anterior pituitary response in patients with idiopathic hypothalamic hypogonadism caused by pulsatile GnRH therapy and testosterone replacement

J. Schopohl, J. Mojto, M. Losa, G. Mehltretter, O. A. Muller, K. Von Werder

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective. This study evaluated in male patients with idiopathic hypothalamic hypogonadism the effect of pulsatile GnRH therapy or testosterone replacement on the response of all anterior pituitary hormones to adequate dynamic stimuli. Patients and design. In nine patients with idiopathic hypothalamic hypogonadism - mean age 21 ± 1 (mean ± SE) - a combined pituitary stimulation (CPS) with 200 μg TRH, 100 μg GnRH, 100 μg CRH and 100 μg GRH and an insulin tolerance-test (ITT) with 0.1 U insulin/kg body weight were performed. Both tests were repeated during pulsatile GnRH therapy and thereafter on testosterone replacement. Measurements. Hormone levels were measured by immunometric assays. For statistical analysis the area under the curve (AUC) was used as a measure for hormone response. Results. Testosterone levels did not differ significantly during GnRH therapy (16.6 ± 2.1 nmol/L) and testosterone replacement (18.5 ± 1.7 nmol/L). No significant differences were observed before and during the two treatment modalities for TSH and ACTH. PRL increase was significantly higher during GnRH therapy (AUC: 73580 ± 8940) compared to the rise before treatment (AUC: 36161 ± 5853; p <0.01) and on testosterone replacement (AUC: 49995 ± 6158; p <0.01). The GH response to CPS and ITT was higher under testosterone replacement (AUC: 1826 ± 353 and 1423 ± 125) compared with the pretreatment situation (AUC: 727 ± 115; p <0.05 and 541 ± 110; p <0.01) and also more pronounced than under GnRH therapy (AUC: 1148 ± 180 and 798 ± 129; p <0.05). FSH and LH after CPS rose significantly more during GnRH therapy (AUC: 864 ± 122 and 2215 ± 219) than before (AUC: 418 ± 61 and 1424 ± 277; p <0.01) and on testosterone treatment (342 ± 83 and 1153 ± 323; p <0.05). Conclusion. These results show that GnRH exerts a stimulatory effect on PRL secretion and may modulate GH secretion independently from sex steroids.

Original languageEnglish
Pages (from-to)184-190
Number of pages7
JournalExperimental and Clinical Endocrinology and Diabetes
Volume103
Issue number3
Publication statusPublished - 1995

Fingerprint

Hypogonadism
Gonadotropin-Releasing Hormone
Area Under Curve
Testosterone
Therapeutics
Insulin
Hormones
Anterior Pituitary Hormones
Adrenocorticotropic Hormone
Steroids
Body Weight

Keywords

  • GnRH
  • Hypothalamic hypogonadism
  • Pituitary
  • Releasing hormones
  • Testosterone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Changes in anterior pituitary response in patients with idiopathic hypothalamic hypogonadism caused by pulsatile GnRH therapy and testosterone replacement. / Schopohl, J.; Mojto, J.; Losa, M.; Mehltretter, G.; Muller, O. A.; Von Werder, K.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 103, No. 3, 1995, p. 184-190.

Research output: Contribution to journalArticle

@article{cba43e2ef65d43189389d67a1a76d2c8,
title = "Changes in anterior pituitary response in patients with idiopathic hypothalamic hypogonadism caused by pulsatile GnRH therapy and testosterone replacement",
abstract = "Objective. This study evaluated in male patients with idiopathic hypothalamic hypogonadism the effect of pulsatile GnRH therapy or testosterone replacement on the response of all anterior pituitary hormones to adequate dynamic stimuli. Patients and design. In nine patients with idiopathic hypothalamic hypogonadism - mean age 21 ± 1 (mean ± SE) - a combined pituitary stimulation (CPS) with 200 μg TRH, 100 μg GnRH, 100 μg CRH and 100 μg GRH and an insulin tolerance-test (ITT) with 0.1 U insulin/kg body weight were performed. Both tests were repeated during pulsatile GnRH therapy and thereafter on testosterone replacement. Measurements. Hormone levels were measured by immunometric assays. For statistical analysis the area under the curve (AUC) was used as a measure for hormone response. Results. Testosterone levels did not differ significantly during GnRH therapy (16.6 ± 2.1 nmol/L) and testosterone replacement (18.5 ± 1.7 nmol/L). No significant differences were observed before and during the two treatment modalities for TSH and ACTH. PRL increase was significantly higher during GnRH therapy (AUC: 73580 ± 8940) compared to the rise before treatment (AUC: 36161 ± 5853; p <0.01) and on testosterone replacement (AUC: 49995 ± 6158; p <0.01). The GH response to CPS and ITT was higher under testosterone replacement (AUC: 1826 ± 353 and 1423 ± 125) compared with the pretreatment situation (AUC: 727 ± 115; p <0.05 and 541 ± 110; p <0.01) and also more pronounced than under GnRH therapy (AUC: 1148 ± 180 and 798 ± 129; p <0.05). FSH and LH after CPS rose significantly more during GnRH therapy (AUC: 864 ± 122 and 2215 ± 219) than before (AUC: 418 ± 61 and 1424 ± 277; p <0.01) and on testosterone treatment (342 ± 83 and 1153 ± 323; p <0.05). Conclusion. These results show that GnRH exerts a stimulatory effect on PRL secretion and may modulate GH secretion independently from sex steroids.",
keywords = "GnRH, Hypothalamic hypogonadism, Pituitary, Releasing hormones, Testosterone",
author = "J. Schopohl and J. Mojto and M. Losa and G. Mehltretter and Muller, {O. A.} and {Von Werder}, K.",
year = "1995",
language = "English",
volume = "103",
pages = "184--190",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "3",

}

TY - JOUR

T1 - Changes in anterior pituitary response in patients with idiopathic hypothalamic hypogonadism caused by pulsatile GnRH therapy and testosterone replacement

AU - Schopohl, J.

AU - Mojto, J.

AU - Losa, M.

AU - Mehltretter, G.

AU - Muller, O. A.

AU - Von Werder, K.

PY - 1995

Y1 - 1995

N2 - Objective. This study evaluated in male patients with idiopathic hypothalamic hypogonadism the effect of pulsatile GnRH therapy or testosterone replacement on the response of all anterior pituitary hormones to adequate dynamic stimuli. Patients and design. In nine patients with idiopathic hypothalamic hypogonadism - mean age 21 ± 1 (mean ± SE) - a combined pituitary stimulation (CPS) with 200 μg TRH, 100 μg GnRH, 100 μg CRH and 100 μg GRH and an insulin tolerance-test (ITT) with 0.1 U insulin/kg body weight were performed. Both tests were repeated during pulsatile GnRH therapy and thereafter on testosterone replacement. Measurements. Hormone levels were measured by immunometric assays. For statistical analysis the area under the curve (AUC) was used as a measure for hormone response. Results. Testosterone levels did not differ significantly during GnRH therapy (16.6 ± 2.1 nmol/L) and testosterone replacement (18.5 ± 1.7 nmol/L). No significant differences were observed before and during the two treatment modalities for TSH and ACTH. PRL increase was significantly higher during GnRH therapy (AUC: 73580 ± 8940) compared to the rise before treatment (AUC: 36161 ± 5853; p <0.01) and on testosterone replacement (AUC: 49995 ± 6158; p <0.01). The GH response to CPS and ITT was higher under testosterone replacement (AUC: 1826 ± 353 and 1423 ± 125) compared with the pretreatment situation (AUC: 727 ± 115; p <0.05 and 541 ± 110; p <0.01) and also more pronounced than under GnRH therapy (AUC: 1148 ± 180 and 798 ± 129; p <0.05). FSH and LH after CPS rose significantly more during GnRH therapy (AUC: 864 ± 122 and 2215 ± 219) than before (AUC: 418 ± 61 and 1424 ± 277; p <0.01) and on testosterone treatment (342 ± 83 and 1153 ± 323; p <0.05). Conclusion. These results show that GnRH exerts a stimulatory effect on PRL secretion and may modulate GH secretion independently from sex steroids.

AB - Objective. This study evaluated in male patients with idiopathic hypothalamic hypogonadism the effect of pulsatile GnRH therapy or testosterone replacement on the response of all anterior pituitary hormones to adequate dynamic stimuli. Patients and design. In nine patients with idiopathic hypothalamic hypogonadism - mean age 21 ± 1 (mean ± SE) - a combined pituitary stimulation (CPS) with 200 μg TRH, 100 μg GnRH, 100 μg CRH and 100 μg GRH and an insulin tolerance-test (ITT) with 0.1 U insulin/kg body weight were performed. Both tests were repeated during pulsatile GnRH therapy and thereafter on testosterone replacement. Measurements. Hormone levels were measured by immunometric assays. For statistical analysis the area under the curve (AUC) was used as a measure for hormone response. Results. Testosterone levels did not differ significantly during GnRH therapy (16.6 ± 2.1 nmol/L) and testosterone replacement (18.5 ± 1.7 nmol/L). No significant differences were observed before and during the two treatment modalities for TSH and ACTH. PRL increase was significantly higher during GnRH therapy (AUC: 73580 ± 8940) compared to the rise before treatment (AUC: 36161 ± 5853; p <0.01) and on testosterone replacement (AUC: 49995 ± 6158; p <0.01). The GH response to CPS and ITT was higher under testosterone replacement (AUC: 1826 ± 353 and 1423 ± 125) compared with the pretreatment situation (AUC: 727 ± 115; p <0.05 and 541 ± 110; p <0.01) and also more pronounced than under GnRH therapy (AUC: 1148 ± 180 and 798 ± 129; p <0.05). FSH and LH after CPS rose significantly more during GnRH therapy (AUC: 864 ± 122 and 2215 ± 219) than before (AUC: 418 ± 61 and 1424 ± 277; p <0.01) and on testosterone treatment (342 ± 83 and 1153 ± 323; p <0.05). Conclusion. These results show that GnRH exerts a stimulatory effect on PRL secretion and may modulate GH secretion independently from sex steroids.

KW - GnRH

KW - Hypothalamic hypogonadism

KW - Pituitary

KW - Releasing hormones

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=0029043136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029043136&partnerID=8YFLogxK

M3 - Article

C2 - 7584521

AN - SCOPUS:0029043136

VL - 103

SP - 184

EP - 190

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 3

ER -